Clinical Trial

Mesenchymal CTC Ratio Dynamics Predicts Response and Survival in Pancreatic Ductal Adenocarcinoma With Neoadjuvant/Conversion Therapy

Name: Mesenchymal CTC Ratio Dynamics Predicts Response and Survival in Pancreatic Ductal Adenocarcinoma With Neoadjuvant/Conversion Therapy — clinical trial record (NCT07329920)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Completed

View on ClinicalTrials.gov →

Summary

The aim of this study was to evaluate the clinical utility of mesenchymal CTC ratio dynamics as a real-time biomarker for PDAC patients with neoadjuvant therapy.

Protocol Amendment History 1 amendment

This ClinicalTrials.gov record has been amended once since 2025-12-27.

Trial Details

NCT Number	NCT07329920
Lead Sponsor	Guo ShiWei
Conditions	Pancreatic Ductal Adenocarcinoma (PDAC), Circulating Tumor Cells (CTCs), Neoadjuvant Therapy
Enrollment	300 participants
Start Date	2018-07-10
Primary Completion	2021-09-15 (estimated)
Study Completion	2025-10-01 (estimated)
Updated on ClinicalTrials.gov	2026-01-12